Symphogen has signed an exclusive worldwide license agreement with Merck for Sym004 an investigational antibody mixture targeting the epidermal growth factor receptor EGFR.
Symphogen has signed an exclusive worldwide license agreement with Merck for Sym004, an investigational antibody mixture targeting the epidermal growth factor receptor (EGFR).
RESEARCH TRIANGLE PARK, N.C., July 24, 2012 /PRNewswire/ -- Chimerix, Inc. today announced the execution of a license agreement granting Merck, known as MSD outside the United States and Canada, exclu…
AstraZeneca and Rigel Pharmaceuticals have entered into exclusive worldwide license agreement for the global development and commercialization of R256.
